Are you Dr. Markham?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 40 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
615 N Wolfe St
Baltimore, MD 21205Phone+1 410-955-9601Fax+1 410-614-8263
Summary
- Dr. Richard Markham, MD is an infectious disease specialist in Baltimore, Maryland. He is currently licensed to practice medicine in Maryland.
Education & Training
Brigham and Women's HospitalResidency, Internal Medicine, 1977 - 1979
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1973 - 1975
Albert Einstein College of MedicineClass of 1972
Certifications & Licensure
MD State Medical License 1976 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- Brief Communication: Combination of an MIP3α-Antigen Fusion Therapeutic DNA Vaccine With Treatments of IFNα and 5-Aza-2'Deoxycytidine Enhances Activated Effector CD8+ ...Kaitlyn Fessler, Jiaqi Zhang, Avinaash K Sandhu, Yinan Hui, Aakanksha R Kapoor
Journal of Immunotherapy. 2025-01-01 - Combination of a MIP3α-antigen fusion therapeutic DNA vaccine with treatments of IFNα and 5-Aza-2'Deoxycytidine enhances activated effector CD8+ T cells expressing CD1...Kaitlyn Fessler, Jiaqi Zhang, Avinaash K Sandhu, Yinan Hui, Aakanksha R Kapoor
Research Square. 2024-08-20 - A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses.James Tristan Gordy, Yinan Hui, Courtney Schill, Tianyin Wang, Fengyixin Chen
Frontiers in Immunology. 2024-01-01
Grant Support
- Use Of Clonal Genotyping To Predict Resistance Development In Art-Naive IDUNational Institute On Drug Abuse2008–2012
- Effect Of Cocaine And LTR Polymorphism On HIV-1 PathogenesisNational Institute On Drug Abuse2008–2012
- Training: Molecular &Cellular Bases Of Infectious DiseasesNational Institute Of Allergy And Infectious Diseases2010–2011
- Roche 454 Genome Sequencer FlxNational Center For Research Resources2010
- Development Of Transformed Lactobacilli As A MicrobicideNational Institute Of Allergy And Infectious Diseases2009–2010
- Development Of A Malaria DNA Vaccine With Enchanced ImmunogenicityNational Institute Of Allergy And Infectious Diseases2008–2009
- Anti-Icam-I Scfv From Lactobacilli As A MicrobicideNational Institute Of Allergy And Infectious Diseases2004–2007
- Anti-Icam-1 Scfv From Lactobacilli As A MicrobicideNational Institute Of Allergy And Infectious Diseases2003–2004
- Drug Abuse And Resistance To Antiretroviral TherapyNational Institute On Drug Abuse2000–2004
- Acquired Immunodeficiency Syndrome ReviewNational Institute Of Allergy And Infectious Diseases2001–2002
- Impact Of Recombination In HIV-1 On Intrahost EvolutionNational Institute Of General Medical Sciences1999–2002
- HIV 1 Immune Activation And Pathogenesis In Drug UsersNational Institute On Drug Abuse1995–1998
- Genetic Determinants Of HIV Infection Of IV Drug UsersNational Institute On Drug Abuse1995–1998
- Model For AIDS TherapyNational Institute Of Allergy And Infectious Diseases1989–1993
- Core--Scid-Hu MouseNational Institute Of Allergy And Infectious Diseases1989–1993
- T Cell Immunity To Extracellular BacteriaNational Institute Of Allergy And Infectious Diseases1989–1991
- T Cell Killing Of Extracellular BacteriaNational Institute Of Allergy And Infectious Diseases1985–1987
